Biocon [BIOCON] vs Glenmark [GLENMARK] Detailed Stock Comparison

Biocon Ltd.

NSE
Loading...

Glenmark Pharmaceuticals Ltd.

NSE
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: Biocon Ltd. wins in 8 metrics, Glenmark Pharmaceuticals Ltd. wins in 12 metrics, with 0 ties. Glenmark Pharmaceuticals Ltd. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Biocon Ltd. Glenmark Pharmaceuticals Ltd. Better
P/E Ratio (TTM) 71.84 59.35 Glenmark Pharmaceuticals Ltd.
Price-to-Book Ratio 1.68 6.60 Biocon Ltd.
Debt-to-Equity Ratio 50.02 12.78 Glenmark Pharmaceuticals Ltd.
PEG Ratio 0.17 3.73 Biocon Ltd.
EV/EBITDA 19.22 15.27 Glenmark Pharmaceuticals Ltd.
Profit Margin (TTM) 3.59% 6.45% Glenmark Pharmaceuticals Ltd.
Operating Margin (TTM) 7.63% 18.34% Glenmark Pharmaceuticals Ltd.
EBITDA Margin (TTM) 7.63% 18.34% Glenmark Pharmaceuticals Ltd.
Return on Equity 3.66% 11.83% Glenmark Pharmaceuticals Ltd.
Return on Assets (TTM) 1.72% 6.52% Glenmark Pharmaceuticals Ltd.
Free Cash Flow (TTM) $17.18B $-15.77B Biocon Ltd.
Dividend Yield 0.26% 0.25% Biocon Ltd.
1-Year Return 17.90% 30.18% Glenmark Pharmaceuticals Ltd.
Price-to-Sales Ratio (TTM) 3.37 3.83 Biocon Ltd.
Enterprise Value $643.51B $615.44B Biocon Ltd.
EV/Revenue Ratio 3.82 3.73 Glenmark Pharmaceuticals Ltd.
Gross Profit Margin (TTM) 67.91% 66.69% Biocon Ltd.
Revenue per Share (TTM) $133 $585 Glenmark Pharmaceuticals Ltd.
Earnings per Share (Diluted) $4.87 $37.74 Glenmark Pharmaceuticals Ltd.
Beta (Stock Volatility) 0.25 0.29 Biocon Ltd.

Biocon Ltd. vs Glenmark Pharmaceuticals Ltd. Stock Performance Analysis

Loading Price Chart...

BIOCON
GLENMARK

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Biocon Ltd.-0.70%1.66%-3.27%10.34%6.50%7.30%
Glenmark Pharmaceuticals Ltd.-0.79%-0.65%-7.28%-0.86%8.61%6.44%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Biocon Ltd.17.90%71.09%5.03%250.57%603.49%1,357.39%
Glenmark Pharmaceuticals Ltd.30.18%238.36%239.44%186.23%606.58%3,294.97%

Performance & Financial Health Analysis: Biocon Ltd. vs Glenmark Pharmaceuticals Ltd.

MetricBIOCONGLENMARK
Market Information
Market Cap i₹566.52B₹662.58B
Market Cap CategoryLarge capLarge cap
10 Day Avg. Volume i2,496,867495,337
90 Day Avg. Volume i3,790,310640,502
Last Close₹416.05₹2,156.60
52 Week Range₹331.00 - ₹440.40₹1,625.00 - ₹2,474.00
% from 52W High-5.53%-12.83%
All-Time High₹487.75 (Dec 21, 2020)₹2,471.20 (Apr 29, 2026)
% from All-Time High-14.70%-12.73%
Growth Metrics
Quarterly Revenue Growth0.09%0.15%
Quarterly Earnings Growth4.73%0.16%
Financial Health
Profit Margin (TTM) i0.04%0.06%
Operating Margin (TTM) i0.08%0.18%
Return on Equity (TTM) i0.04%0.12%
Debt to Equity (MRQ) i50.0212.78
Cash & Liquidity
Book Value per Share (MRQ)₹207.92₹339.57
Cash per Share (MRQ)₹45.84₹95.34
Operating Cash Flow (TTM) i₹17.78B₹2.11B
Levered Free Cash Flow (TTM) i₹10.13B₹10.47B
Dividends
Last 12-Month Dividend Yield i0.26%0.25%
Last 12-Month Dividend i₹1.00₹5.00

Valuation & Enterprise Metrics Analysis: Biocon Ltd. vs Glenmark Pharmaceuticals Ltd.

MetricBIOCON (Apr 26, 2026)GLENMARK (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) i71.8459.35
Forward P/E i38.5627.98
PEG Ratio i0.173.73
Price to Sales (TTM) i3.373.83
Price to Book (MRQ) i1.686.60
Market Capitalization
Market Capitalization i₹566.52B₹662.58B
Enterprise Value i₹643.51B₹615.44B
Enterprise Value Metrics
Enterprise to Revenue i3.823.73
Enterprise to EBITDA i19.2215.27
Risk & Other Metrics
Beta i0.250.29
Book Value per Share (MRQ) i₹207.92₹339.57

Financial Statements Comparison: Biocon Ltd. vs Glenmark Pharmaceuticals Ltd.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricBIOCON (2025)GLENMARK (2025)
Revenue/Sales i150.52B131.46B
Cost of Goods Sold i51.98B47.57B
COGS % of Revenue i34.5%36.2%
Gross Profit i98.54B83.88B
Gross Margin i65.5%63.8%
Research & Development i6.34BN/A
Operating Income (EBIT) i16.26B18.68B
Operating Margin i10.8%14.2%
EBITDA i33.60B24.68B
EBITDA Margin i22.3%18.8%
Pre-Tax Income i18.87B13.99B
Pre-Tax Income % of Revenue i12.5%10.6%
Income Tax i4.57B3.52B
Income Tax % of Revenue i3.0%2.7%
Net Income (Profit) i14.29B10.47B
Profit Margin i9.5%8.0%

Balance Sheet & Liquidity Metrics

MetricBIOCON (2025)GLENMARK (2025)
Cash & Equivalents i32.27B16.76B
Total Current Assets i162.86B92.95B
Total Current Assets % of Revenue i108.2%70.7%
Total Current Liabilities i143.34B59.67B
Total Current Liabilities % of Revenue i95.2%45.4%
Long-Term Debt i129.45B6.99B
Long-Term Debt % of Revenue i86.0%5.3%
Total Shareholders Equity i277.13B88.49B
Retained Earnings i189.59B87.99B
Retained Earnings % of Revenue i126.0%66.9%
Property, Plant & Equipment i4.32B33.19B

Cash Flow Statement Comparison

MetricBIOCON (2025)GLENMARK (2025)
Operating Cash Flow i17.78B2.11B
Operating Cash Flow % of Revenue i11.8%1.6%
Capital Expenditures i-21.36B-7.47B
Free Cash Flow i17.18B-15.77B
FCF Margin i11.4%-12.0%
Debt Repayment i-97.70B-1.41B
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricBIOCONGLENMARK
Shares Short iN/AN/A
Short Ratio iN/AN/A
Short % of Float iN/AN/A
Shares Outstanding i1.62B282.20M
Float Shares i583.07M141.58M
% Held by Insiders i54.07%48.96%
% Held by Institutions i24.88%26.61%
% Held by Public i21.05%24.43%

Dividend Analysis & Yield Comparison: Biocon Ltd. vs Glenmark Pharmaceuticals Ltd.

MetricBIOCONGLENMARK
Last 12-Month Dividend i₹1.00₹5.00
Last 12-Month Dividend Yield i0.26%0.25%
3-Year Avg Annual Dividend i₹1.33₹3.33
3-Year Avg Dividend Yield i0.36%0.18%
3-Year Total Dividends i₹4.00₹10.00
Ex-Dividend DateJul 04, 2025Oct 03, 2025